[HTML][HTML] Real-world experience in treatment of patients with non-small-cell lung cancer with Braf or Cmet exon 14 skipping mutations
U Janzic, W Shalata, K Szymczak… - International Journal of …, 2023 - mdpi.com
BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in
these cases for the first and second line is not clear. An international registry was created for …
these cases for the first and second line is not clear. An international registry was created for …
[HTML][HTML] New insights of miRNA molecular mechanisms in breast cancer brain metastasis and therapeutic targets
BM Hussen, KH Abdullah, SR Abdullah… - Non-coding RNA …, 2023 - Elsevier
Brain metastases in breast cancer (BC) patients are often associated with a poor prognosis.
Recent studies have uncovered the critical roles of miRNAs in the initiation and progression …
Recent studies have uncovered the critical roles of miRNAs in the initiation and progression …
Prognostic impacts of extracranial metastasis on non‐small cell lung cancer with brain metastasis: A retrospective study based on surveillance, epidemiology, and end …
M Wang, Q Wu, J Zhang, G Qin, T Yang, Y Liu… - Cancer …, 2021 - Wiley Online Library
This study was designed to investigate the prognostic value of the number and sites of
extracranial metastasis (ECM) in NSCLC patients with BM. NSCLC patients with BM from the …
extracranial metastasis (ECM) in NSCLC patients with BM. NSCLC patients with BM from the …
[HTML][HTML] Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment
I Averbuch, R Tschernichovsky, S Yust-Katz… - Journal of Neuro …, 2024 - Springer
Methods Outcome data were collected for patients with advanced NSCLC attending a
tertiary medical center between 2015 and 2020. Patients were stratified according to BM …
tertiary medical center between 2015 and 2020. Patients were stratified according to BM …
[HTML][HTML] Real-World management and outcomes of crizotinib-treated ROS1-rearranged NSCLC: A retrospective Canadian Cohort
AJW Gibson, A Box, WY Cheung, ML Dean… - Current …, 2022 - mdpi.com
The use, safety and effectiveness of crizotinib as part of the management of ROS1-
rearranged NSCLC patients in a real-world Canadian clinical cohort was the focus of this …
rearranged NSCLC patients in a real-world Canadian clinical cohort was the focus of this …
Next-Generation Cell-Based Therapies to Combat Metastatic Brain Tumor
KSR Pai - Recent Advances in Pharmaceutical Innovation and …, 2023 - Springer
Glioblastoma (GBM) is a grade IV aggressive type brain tumor that causes rapid proliferation
and growth rate. The average survival period is 14 to 16 months after diagnosis and the …
and growth rate. The average survival period is 14 to 16 months after diagnosis and the …
Brain Metastases: Current and Future Pharmacological Treatment
ES Horta, T Walbert - Cancer Metastasis Through the Lymphovascular …, 2022 - Springer
Solid tumor metastasis to the brain is a frequent event that increases morbidity and mortality
of patients suffering from an already life-threatening disease. Pharmacological treatment …
of patients suffering from an already life-threatening disease. Pharmacological treatment …
Perbandingan Efikasi Afatinib dan Erlotinib Sebagai Terapi Lini Pertama Kanker Paru Jenis Adenokarsinoma Dengan Mutasi EGFR
BDA Hapsari - 2021 - digilib.uns.ac.id
Latar Belakang: Data Global burden of cancer study (GLOBOCAN) tahun 2020
menyebutkan prevalensi kanker paru di dunia menempati urutan pertama pada laki-laki dan …
menyebutkan prevalensi kanker paru di dunia menempati urutan pertama pada laki-laki dan …
Importância do Alectinib na terapêutica de doentes com metáteses cerebrais
PAPC Branco - 2021 - estudogeral.uc.pt
Introdução: O carcinoma pulmonar de não pequenas células (CPCNP) com rearranjo
anaplastic lymphoma kinase (ALK) positivo em estádio avançado permite uma abordagem …
anaplastic lymphoma kinase (ALK) positivo em estádio avançado permite uma abordagem …